Panacea Biotec Hits 5% Upper Circuit on UNICEF Order Win
Panacea Biotec share price jumped 5 per cent to hit its upper circuit limit of ₹456.25 Shares of Panacea Biotec , a small-cap pharmaceutical company, surged by 5% to hit the upper circuit limit on Thursday, December 26, following the announcement that the company had won a significant order from UNICEF. The order, valued at ₹127 crore, is for the supply of 115 million doses of the bivalent oral polio vaccine (bOPV) scheduled for delivery in 2025. In an exchange filing on December 24, Panacea Biotec revealed, "We are pleased to inform that Panacea Biotec Limited has received a Letter of Award from UNICEF for the supply of 115 million doses of its bivalent oral polio vaccine (bOPV), worth approximately US$ 14.95 million (₹127 crore) in calendar year 2025." Stock Price Impact Following the announcement, Panacea Biotec's share price jumped 5% to ₹456.25, hitting the upper circuit limit. At 10:45 am, the stock was trading 4% higher at ₹452. The stock had previously touched ...